Expert perspectives on AI, data, and the future of clinical development.

Real-Time Trials Are Coming: Is Pharma Ready?

Clinical trials were not designed for real-time decision-making. Most teams are still waiting days or weeks for signals to surface, by which point the window to act has often passed. The model is changing, and the question is no longer whether real-time trials are coming. It is whether pharma is ready for them.

May 19, 2026

read ↗

The FDA’s New Operating Model for Clinical Development

Two FDA announcements. One fundamental shift in how therapies are developed, evaluated, and delivered.

May 1, 2026

read ↗

The Vivo Control Tower Powers OmniScience’s Integration with Veeva CTMS and TMF, Delivering Agentic AI Insights Across Clinical Trials

Vivo delivers unified clinical trial intelligence across an ever-growing collection of clinical trial data sources, accelerating real-time insights and action for biopharma sponsors.

April 8, 2026

read ↗

The FDA’s ‘One Trial’ announcement signals the most consequential change for clinical development in decades

Why the future of drug development demands that evidence is continuously captured and translated into knowledge in real time.

March 3, 2026

read ↗

SCOPE 2026: What Real-Time Clinical Trial Intelligence Looks Like in Practice

SCOPE 2026: what changes when AI enables continuous, real-time trial intelligence, and why the results matter for patients.

February 9, 2026

read ↗

From Insight to Action: How OmniScience Is Unlocking a New Way to Run Trials

As traditional reactive oversight struggles under modern trial complexity, Vivo enables continuous, event-based monitoring so sponsors can detect risk while there is still time to act.

February 2, 2026

read ↗

OmniScience Selected as Finalist for Prestigious Duke Clinical Research Institute Program

Partnering with one of the world’s leading academic research organizations to accelerate smarter, more efficient clinical trials.

October 23, 2025

read ↗

OmniScience Named a Vendor to Watch in Inaugural IDC MarketScape Report on AI in Clinical Trials

Recognized for innovation in AI-driven clinical trial solutions, OmniScience earns a spot on IDC’s list of vendors to watch

October 20, 2025

read ↗

OmniScience Accepted into PharmStars Accelerator Fall 2025 Cohort

Selected from a highly competitive field, OmniScience joins PharmStars’ Fall 2025 cohort

September 17, 2025

read ↗

LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab Insights

Together we’re unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes.

September 15, 2025

read ↗

OmniScience Accepted into DayOne Accelerator’s 2025 HealthTech x Pharma R&D Cohort

One of just 10 companies selected from a global pool of over 200 applicants, OmniScience joins DayOne to advance AI innovation in clinical trials.

August 21, 2025

read ↗

OmniScience Selected to Compete in Prestigious DPHARM Idol Disrupt 2025

Selected to compete among the industry’s boldest innovators at DPHARM Idol Disrupt 2025.

August 15, 2025

read ↗

ICH E6(R3) and the Future of Risk-Based Oversight: Are We Ready?

As global trials grow more complex, traditional oversight models are falling behind. To meet the new mandate for real-time, risk-based monitoring, sponsors must evolve from manual reviews to intelligent, predictive systems.

July 23, 2025

read ↗

OmniScience CEO Angela Holmes Named AI Entrepreneur of the Year by Women in AI

Celebrating visionary leadership in clinical research AI and the transformative potential of agentic systems.

June 17, 2025

read ↗

OmniScience Accepted into Google for AI Startups Cloud program to accelerate AI Innovation in Clinical Trials

OmniScience taps into Google’s global network to scale Vivo and reshape clinical development.

June 11, 2025

read ↗

Rewriting the Rules of Clinical Development & How Agentic AI Delivers Faster, Smarter Trials

How agentic AI helps clinical trial teams cut costs, reduce delays, and make smarter decisions in real time.

June 4, 2025

read ↗

An Inflection Point: How Clinical Development Teams Can Align with the FDA’s Adoption of GenAI

GenAI is reshaping how regulators approach clinical trials, offering clinical development teams the opportunity to adopt practices and tools that facilitate faster, smarter, and more transparent trial operations.

May 13, 2025

read ↗

OmniScience Joins NVIDIA Inception Program to Accelerate AI Innovation in Clinical Trials

Vivo’s expansion gains momentum through acceptance to NVIDIA Inception’s innovation ecosystem.

May 9, 2025

read ↗

The OmniScience Board: A Track Record of Innovation and Commercial Success in Clinical Trials

How OmniScience boardmembers Linda Blackerby and Nicola Marlin are applying their combined experience to reimagine the future of clinical trials with OmniScience's platform, Vivo.

April 15, 2025

read ↗

OmniScience is Accepted Into JLABS

OmniScience has been accepted into JLABS to advance Vivo, the first genAI Clinical Trial Control Tower.

April 3, 2025

read ↗

OmniScience CEO Angela Holmes Nominated for Women in AI Awards North America 2025

Angela Holmes, has been nominated for the Women in AI Awards North America 2025, this prestigious recognition highlights the contributions of women driving AI innovation across North America.

February 20, 2025

read ↗

OmniScience Welcomes Colin Hendricks as CTO

Scaling our data scientists’ leading edge agentic AI innovations for the clinical research industry.

February 19, 2025

read ↗

Integro Theranostics and OmniScience Partner to Improve Cancer Clinical Study Outcomes

Advancing Oncology Care: Integro Theranostics partners with OmniScience to Transform Clinical Trial Data through AI Powered Innovation.

February 12, 2025

read ↗

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

HOUSTON & BOCA RATON, Fla. December 4th, 2024 - OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease (AD) clinical trial (the “AD02 trial”) using OmniScience’s flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents an innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management.

December 4, 2024

read ↗

OmniScience’s clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS Summit 2024 Innovation Showcase

Patients are waiting: The CNS Summit brings together life sciences leaders who aren’t afraid to challenge the status quo when it comes to the development of new treatments for patients

November 25, 2024

read ↗

Kris Kuhner Joins OmniScience as Senior Vice President of Business Development

Bringing over 20 years of experience in clinical trials, Kris joins OmniScience to drive strategic growth and expand partnerships in the life sciences industry

November 22, 2024

read ↗

Vivo, OmniScience’s genAI-powered clinical trial control tower, wins 2024 The Whale Tank competition at Innovation Network Gathering

OmniScience makes waves with Vivo, a market-first genAI AI solution that amplifies clinical development teams’ ability to accelerate treatments to patients

November 13, 2024

read ↗

Revolutionizing Pediatric Mental Health Monitoring: futuresTHRIVE Licenses OmniScience’s Vivo for Early Detection in Children

Designed for young, not-yet-reading children, tScreen uses Vivo’s AI-driven insights to monitor mental health indicators, providing early detection and empowering caregivers with actionable insights.

November 11, 2024

read ↗

Revolutionize Trial Oversight with genAI: On-Demand Insights to Improve Clinical Trial Success

The genAI Clinical Trial Revolution: How genAI amplifies ClinDev teams to manage the data explosion, enabling faster and safer delivery of treatments to patients.

November 7, 2024

read ↗

Eliminate the Wait: Real-Time Data Drives Faster, Smarter Trials

Clinical development teams often find themselves waiting: waiting for the next interim analysis or, in some cases, for the trial's end to gain access to the data that drives critical decisions. This lack of timely insights creates blind spots that slow down progress, introduce operational risks, and leave teams playing catch-up with trial performance issues.

October 23, 2024

read ↗

Accelerating Adoption of DHTs within Clinical Trials: Lowering the Barrier of Entry Through Data Unification

Modern clinical trials are using digital health technologies to better understand diseases, categorize patients, and measure treatment effectiveness. However, their adoption is limited by the added burden on sponsors, sites, clinicians, and data management systems, necessitating changes in clinical trial infrastructure.

August 29, 2024

read ↗

Advancing Digital Endpoints in Clinical Trials: OmniScience Announces Strategic Partnership with DiMe

Houston, Texas, June 6th, 2024 – OmniScience, a leader in applying AI to clinical research, announces a strategic partnership with DiMe to advance digital measurement in clinical trials.

June 6, 2024

read ↗

Unlocking the Power of Genetic Algorithms: A Revolution in Precision Diagnostics

Innovative tools are urgently needed to tackle the complex landscape of medical diagnostics, considering gender, race, age, genomics, transcriptomics, metabolomics, proteomics, and other data. Explore how Genetic Algorithms (GAs), inspired by natural selection, navigate vast feature spaces with unparalleled efficiency.

February 21, 2024

read ↗

OmniScience Welcomes Michael Bell, Ph.D. as Vice President of Product

HOUSTON, Texas, November 1st, 2023 - OmniScience , a pioneering AI solutions consultancy specializing in life sciences, is thrilled to announce the appointment of Michael Bell, Ph.D., as the company's Vice President of Product.

November 1, 2023

read ↗

Revolutionizing Clinical Trials: How AI is Improving Clinical Trial Retention

Artificial intelligence has great potential to transform clinical trials by enhancing retention, aiding in participant recruitment, personalizing engagement, detecting dropout risk, predicting intervention strategies, and monitoring adverse events to improve benefiting participants, sites, and sponsors – all at reduced costs.

October 9, 2023

read ↗

ANCP poster abstract publication with Janssen

OmniScience + Janssen abstract publication at the American College of Neuropsychopharmacology 61st Annual Meeting.

February 1, 2023

read ↗